Larvol Delta - Exelixis-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2022-Financial-Results-Provides-2023-Financial-Guidance-and-Outlines-Key-Priorities-and-Milestones-for-2023

XL102 - Exelixis

alphalex-exatecan (CBX-12) - Cybrexa Therap, Exelixis

https://www.businesswire.com/news/home/20230108005042/en/Exelixis-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2022-Financial-Results-Provides-2023-Financial-Guidance-and-Outlines-Key-Priorities-and-Milestones-for-2023

Jan 9, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next